Know Cancer

or
forgot password

    • cancer clinical trials in germantown, TN

    • A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
    GSK Investigational Site
    Germantown, Tennessee 38138
    Cancer
    Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
    Breast Clinic of Memphis
    Germantown, Tennessee 38138
    Breast Cancer
    Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
    Gastroenterology Center of the MidSouth PC
    Germantown, Tennessee 38138
    Crohn's Disease
    PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
    The Jones Clinic
    Germantown, Tennessee 38138
    Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
    Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
    The Jones Clinic
    Germantown, Tennessee 38138
    Locally Recurrent or Metastatic Breast Cancer
    A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
    The Jones Clinic
    Germantown, Tennessee 38138
    Renal Cell Carcinoma
    GSK1120212 Food-effect Study
    GSK Investigational Site
    Germantown, Tennessee 38138
    Cancer
    Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
    Gastro One
    Germantown, Tennessee 38138
    Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
    Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors
    GSK Investigational Site
    Germantown, Tennessee 38138
    Solid Tumors
    Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
    Gastro One
    Germantown, Tennessee 38138
    Crohn's Disease
    Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
    GSK Investigational Site
    Germantown, Tennessee 38138
    Cancer